Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 28, 2014; 20(4): 1095-1106
Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.1095
Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis
Zheng-Xu Wang, Jun-Xia Cao, Zhi-Ping Liu, Yu-Xin Cui, Chun-Yun Li, Duo Li, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li
Zheng-Xu Wang, Jun-Xia Cao, Chun-Yun Li, Duo Li, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li, Biotherapy Center, the General Hospital of Beijing Military Command, Beijing 100700, China
Zhi-Ping Liu, Department of Immunology, St Jude Children’s Research Hospital, Memphis, TN 38105, United States
Yu-Xin Cui, School of Cellular and Molecular Medicine, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom
Author contributions: Wang ZX designed the research; Cao JX and Li CY performed the research; Liu ZP and Cui YX contributed new reagents or analytic tools; Cao JX, Li CY, Li D, Zhang XY, Liu JL and Li JL analyzed data; Wang ZX, Cao JX, Liu ZP and Cui YX wrote the paper.
Supported by National Natural Science Foundation of China, No. 31171427 and No. 30971651 to Wang ZX; National Natural Science Foundation of China, No. 30700974 to Cao JX; and Postdoctoral Foundation of China, No. 20060400775 to Cao JX
Correspondence to: Zheng-Xu Wang, MD, PhD, Associate Professor, Director of Biotherapy Center, the General Hospital of Beijing Military Command, No.5 of Nan Men Cang Rd, Dongcheng District, Beijing 100700, China. zhxwang18@hotmail.com
Telephone: +86-10-66721169 Fax: +86-10-64038276
Received: September 10, 2013
Revised: October 28, 2013
Accepted: November 12, 2013
Published online: January 28, 2014
Processing time: 138 Days and 9.1 Hours
Core Tip

Core tip: A growing body of knowledge on tumor immunosurveillance and loss thereof has contributed to the refinement of anti-tumor immunotherapy. The aim of our meta-analysis was to determine whether an association exists between dendritic cell (DC)-cytokine-induced killer (CIK) cell therapy combined with chemotherapy and chemotherapy alone. Our analysis demonstrates that DC-CIK therapy improved 1, 2 and 3-year overall survival, 1, 2 and 3-year disease-free survival, overall response rate and immune indices in colon cancer. In all, the combination of DC-CIK immunotherapy and chemotherapy was superior in prolonging the survival time and enhancing immunological responses, suggesting the possible application of this promising adjuvant immunotherapy in colon cancer.